Examining the Phase 1 Clinical Data for CTX310 Targeting ANGPTL3 Editing in Severe Dyslipidemia from CRISPR Therapeutics

Scheduled for:Dec 30, 2026 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A cardiologist or lipidologist specializing in severe dyslipidemias and inherited lipid disorders, experienced in triglyceride- and LDL-lowering treatment strategies for high-risk patients. The expert should be familiar with ANGPTL3 biology, current therapeutic landscapes for severe hypertriglyceridemia and familial hypercholesterolemia, and the clinical interpretation of lipid-modifying outcomes. Experience with emerging gene-editing therapies, LNP delivery platforms, and long-term cardiovascular risk reduction strategies is preferred.

Interview Goal

The interview aims to explore the clinical and translational implications of the first-in-human Phase 1 results for CTX310, an in vivo CRISPR/Cas9 therapy targeting ANGPTL3. Discussion will focus on the durability and magnitude of triglyceride and LDL lowering after a single IV dose, the meaning of deep ANGPTL3 suppression, safety and tolerability considerations for systemic gene-editing approaches, the potential positioning of CTX310 for severe or refractory dyslipidemias, and the broader impact of one-time gene-editing therapies on cardiovascular disease prevention and long-term patient adherence.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.